Apexigen is a Biotech company based in San Carlos, California. It has raised $158M in total funding. Latest round: Series C.
Apexigen funding overview
Apexigen is a Biotech company based in San Carlos, California. Apexigen has raised $158M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in March 2020. The round record for Apexigen runs through 2020; nothing later has been disclosed. Investors on record include 3E Bioventures Capital, Decheng Capital, Oceanpine Capital, SV Tech Ventures, VI Ventures, CDIB Capital Group and 3 others. 9 distinct backers are named across the disclosed rounds.
Apexigen at a glance
Total raised
$158M
Latest round
Series C
Latest round date
March 2020
Industry
Biotech
Headquarters
San Carlos, California
Notable investors
3E Bioventures Capital, Decheng Capital, Oceanpine Capital, SV Tech Ventures, VI Ventures, CDIB Capital Group, Sycamore Ventures, Themes Investment Partners
Frequently asked about Apexigen funding
How much has Apexigen raised?
Apexigen has raised $158M in total disclosed funding across the rounds on record.
Who has invested in Apexigen?
3E Bioventures Capital, Decheng Capital, Oceanpine Capital, SV Tech Ventures, VI Ventures, CDIB Capital Group are named among the investors backing Apexigen.
What was the latest Apexigen funding round?
The most recent disclosed round is a Series C, announced in March 2020.
Where is Apexigen based?
Apexigen is based in San Carlos, California.
What sector does Apexigen operate in?
Apexigen is tracked under Biotech from San Carlos, California, with $158M in disclosed funding.
When did Apexigen last raise?
The last disclosed Apexigen round closed in March 2020 at Series C.
Every Apexigen figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in San Carlos at a similar stage.
